JAMDA
Volume 9, Issue 3 , Pages 137-138 , March 2008

Medications Prescribed by Specialists in Nursing Homes

  • Paul J. Drinka, MD, CMD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Paul J. Drinka, MD, 3379 Bailey Street, Waupaca, WI 54981.

References 

  1. Levenson SA, Saffel DA. The consultant pharmacist and the physician in the nursing home: Roles, relationships, and a recipe for success. J Am Med Dir Assoc. 2007;8:55–64
  2. Dhalla IA, Anderson GM, Mamdani MM, Bronskill SE, Sykora K, Rochon PA. Inappropriate prescribing before and after nursing home admission. J Am Geriatr Soc. 2002;50:995–1000
  3. Lau DT, Kasper JD, Potter DE, Lyles A, Bennett RG. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med. 2005;165:68–74
  4. Veterans Health AdministrationDepartment of Defense. VA/DoD clinical practice guideline for the management of stroke rehabilitation in the primary care setting. In: Washington, DC: Department of Veterans Affairs; 2003;p. 1–44Feb http://www.oqp.med.va.gov/cpg/STR/STR_base.htmAccessed October 31, 2007
  5. American College of Cardiology/American Heart Association Task ForceEuropean Society of Cardiology Committee for Practice Guidelines. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. J Am Coll Cardiol. 2006;48:1064–1108
  6. Levenson SA, Morley JE. Evidence rocks in long-term care, but does it roll?. J Am Med Dir Assoc. 2007;8:493–501
  7. Monane M, Avorn J, Beers MH, Everitt DE. Anticholinergic drug use and bowel function in nursing home patients. Arch Intern Med. 1993;153(5):633–638
  8. Tune LE. Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychiatry. 2000;5:149–153
  9. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment guidelines. Neurology. 2001;56(Suppl 5):S1–S88
  10. Landes AM, Sperry SD, Strauss ME, Geldmacher DS. Apathy in Alzheimer’s disease. J Am Med Dir Assoc. 2001;49:1700–1707
  11. Franco KN, Messinger-Rapport B. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. J Am Med Dir Assoc. 2006;7:201–202
  12. Schneider LS, Tariot PN, Dagerman KS, et al. CATIE-AD Study Group Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355:1525–1538
  13. Howard RJ, Juszczak E, Ballard CG, et al. CALM-AD Trial Group Donepezil for the treatment of agitation in Alzheimer’s disease. N Engl J Med. 2007;357:1382–1392
  14. Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomized comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy (The UK Lamotraine Elderly Study Group). Epilepsy Res. 1999;37:81–87
  15. Rowan AJ, Ramsay RE, Collins JF, et al. The VA Cooperative Study 428 Group New onset geriatric epilepsy: A randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64:1868–1873
  16. Leppik IE. Choosing an antiepileptic: Selecting drugs for older patients with epilepsy. Geriatrics. 2005;60:42–47
  17. Mazza AD, Morley JE. Update on diabetes in the elderly and the application of current therapeutics. J Am Med Dir Assoc. 2007;8:489–492
  18. Department of Health & Human Services (DHHS)Centers for Medicare and Medicaid Services (CMS). Revisions to Appendix P and PP/483. 25(1)/F329/Unnecessary Drugs In: CMS Manual System, Pub (100–07 State Operations Provider Certification, Transmittal 22). 2006;Dec. 15 http://www.cms.hhs.gov/transmittals/downloads/R22SOMA.pdfAccessed November 29, 2007

 The author has no conflict of interest.

PII: S1525-8610(07)00509-9

doi: 10.1016/j.jamda.2007.11.004

JAMDA
Volume 9, Issue 3 , Pages 137-138 , March 2008

Article Tools